KMT2A, lysine methyltransferase 2A, 4297

N. diseases: 535; N. variants: 65
Disease: Leukemia secondary ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 GeneticVariation disease BEFREE These data provide insight into the dynamics of leukemogenesis in secondary leukemia with MLL rearrangement. 18932267 2009
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 GeneticVariation disease BEFREE Topoisomerase II (Topo II) inhibitors are cell cycle-specific DNA-damaging agents and often correlate with secondary leukemia with chromosomal translocations involving the mixed-lineage leukemia/myeloid lymphoid leukemia (MLL) gene on chromosome 11 band q23 (11q23). 16357944 2006
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 Biomarker disease BEFREE In summary, LPP is a newly identified MLL fusion partner in secondary leukemia resulting from topoisomerase inhibitors. 11433529 2001
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 GeneticVariation disease BEFREE The MLL gene rearrangement is closely associated with secondary leukemia with an 11q23 translocation. 9846019 1998
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 GeneticVariation disease BEFREE A t(10;11)(p13;q13) chromosomal abnormality that expresses MLL gene rearrangement has not been reported previously in secondary leukemia. 9648554 1998
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 Biomarker disease BEFREE These results indicate that SJT of ABL and/or CD3 (MLL) genes is associated with the leukemogenesis of secondary leukemia. 9002963 1997
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 GeneticVariation disease BEFREE Translocation t(4;11)(q21;q23) and MLL gene rearrangement in acute lymphoblastic leukemia secondary to anti topoisomerase II anticancer agents. 9168451 1997
CUI: C0856053
Disease: Leukemia secondary
Leukemia secondary 		0.080 GeneticVariation disease BEFREE These results suggest that site specific cleavage within the MLL bcr induced by topoisomerase II inhibitors may be an early step leading to MLL translocations and secondary leukemia. 8639880 1996